drugset / Trial / NCT06582264
A Phase 1b Trial to Evaluate the Safety of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Phase 1b study to evaluate the safety and tolerability of MB310 given to patients who have active mild-to-moderate ulcerative colitis.
Timeline
- Start
- 2024-09-27
- Primary completion
- 2026-01-08
- Completion
- 2026-01-08
Outcome
Met primary endpoint
release “The study which compared MB310, a precision microbiome medicine, with placebo in 29 ulcerative colitis (UC) patients met its primary and secondary objectives” microbiotica.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MB310 | Other / unclassified | — | Oral |
| Background | Vancomycin | Other / unclassified | 125 mg | — |